Axsome Therapeutics, Inc. (AXSM) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en New York City, NY, United States. El CEO actual es Herriot Tabuteau.
AXSM tiene fecha de IPO 2015-11-19, 712 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $9.42B.
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders. The company's lead candidate, AXS-05, is being evaluated for major depressive disorder, treatment-resistant depression, Alzheimer's disease agitation, and smoking cessation across Phase II and Phase III clinical trials. Its pipeline also includes AXS-07 for acute migraine treatment, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia, all in late-stage development. Founded in 2012 and headquartered in New York, Axsome collaborates with leading institutions including Duke University to advance its clinical programs.
